Insider Selling: Medtronic (NYSE:MDT) EVP Sells 1,483 Shares

Medtronic PLC (NYSE:MDT) EVP Harry Kiil sold 1,483 shares of the company’s stock in a transaction on Wednesday, September 16th. The stock was sold at an average price of $93.65, for a total value of $138,882.95. Following the sale, the executive vice president directly owned 42,186 shares in the company, valued at $3,950,718.90. This represents a 3.40% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Medtronic Stock Up 0.3%

NYSE:MDT traded up $0.27 during midday trading on Thursday, reaching $92.87. The company had a trading volume of 10,846,470 shares, compared to its average volume of 8,857,796. The firm has a market capitalization of $118.80 billion, a price-to-earnings ratio of 22.87, a PEG ratio of 2.14 and a beta of 0.56. The stock’s fifty day simple moving average is $88.54 and its 200-day simple moving average is $85.01. Medtronic PLC has a 12-month low of $73.31 and a 12-month high of $106.33. The company has a current ratio of 2.07, a quick ratio of 1.54 and a debt-to-equity ratio of 0.50.

Medtronic (NYSE:MDT) last posted its quarterly earnings results on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.39 by $0.06. The company had revenue of $9.76 billion for the quarter, compared to analyst estimates of $9.55 billion. Medtronic had a return on equity of 14.78% and a net margin of 13.93%.Medtronic’s revenue for the quarter was up 13.7% compared to the same quarter last year. During the same quarter last year, the company earned $1.26 EPS. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. On average, sell-side analysts anticipate that Medtronic PLC will post 5.97 earnings per share for the current fiscal year.

Medtronic Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, October 16th. Investors of record on Friday, September 25th will be issued a $0.72 dividend. The ex-dividend date of this dividend is Friday, September 25th. This represents a $2.88 annualized dividend and a yield of 3.1%. Medtronic’s dividend payout ratio (DPR) is 70.94%.

Institutional Investors Weigh In On Medtronic

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Gradient Investments LLC grew its holdings in Medtronic by 3.9% during the 2nd quarter. Gradient Investments LLC now owns 496,513 shares of the medical technology company’s stock worth $38,842,000 after acquiring an additional 18,509 shares in the last quarter. Czech National Bank lifted its position in shares of Medtronic by 4.7% during the second quarter. Czech National Bank now owns 365,443 shares of the medical technology company’s stock worth $28,589,000 after purchasing an additional 16,292 shares during the last quarter. Cerity Partners LLC grew its stake in Medtronic by 12.7% in the fourth quarter. Cerity Partners LLC now owns 791,015 shares of the medical technology company’s stock worth $75,988,000 after purchasing an additional 89,111 shares in the last quarter. National Pension Service increased its holdings in Medtronic by 1.0% in the fourth quarter. National Pension Service now owns 2,982,411 shares of the medical technology company’s stock valued at $286,490,000 after buying an additional 28,269 shares during the last quarter. Finally, Verity & Verity LLC raised its stake in Medtronic by 5.1% during the second quarter. Verity & Verity LLC now owns 229,707 shares of the medical technology company’s stock valued at $17,970,000 after buying an additional 11,197 shares in the last quarter. 82.06% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts have commented on MDT shares. BTIG Research increased their price objective on shares of Medtronic from $91.00 to $100.00 and gave the company a “buy” rating in a research report on Tuesday, September 1st. Weiss Ratings raised shares of Medtronic from a “hold (c)” rating to a “hold (c+)” rating in a research report on Friday, September 4th. Bank of America increased their target price on Medtronic from $95.00 to $110.00 and gave the company a “buy” rating in a report on Wednesday, September 2nd. Robert W. Baird raised their price target on Medtronic from $91.00 to $100.00 and gave the company a “neutral” rating in a research note on Wednesday, September 2nd. Finally, Needham & Company LLC reaffirmed a “buy” rating on shares of Medtronic in a report on Thursday. Nineteen investment analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat, Medtronic has a consensus rating of “Moderate Buy” and an average price target of $103.92.

More Medtronic News

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Raised outlook and stronger heart-device demand: Medtronic reportedly increased its financial outlook again, supported by continued demand for its cardiac products. This reinforces confidence in near-term earnings growth. Medtronic raises its outlook again as heart device demand keeps climbing
• Positive Sentiment: FDA clearance expands Hugo’s commercial opportunity: The FDA cleared Medtronic’s LigaSure RAS Maryland instrument for use with the Hugo robotic-assisted surgery system. The additional instrument expands the procedures Hugo can support and brings a vessel-sealing technology used in more than 45 million procedures to U.S. robotic surgery customers. Medtronic announces FDA clearance for LigaSure RAS Maryland instrument
• Positive Sentiment: Hugo expansion could diversify revenue: Medtronic is expanding the uses of its Hugo Surgical System, potentially increasing system adoption and recurring instrument revenue as the platform gains broader clinical utility. Should You Buy Medtronic Stock as Its Hugo Surgical Robot Gains Ground?
• Positive Sentiment: Electrophysiology momentum: A comparison with Boston Scientific indicates Medtronic is gaining share in electrophysiology and benefiting from stronger momentum across key franchises, making it a relatively attractive option within the group. BSX versus MDT: Which Electrophysiology Stock Is the Better Bet Now?
• Positive Sentiment: Experienced leadership added: Lara Barghout, former CEO of Recor Medical, was appointed president of Medtronic’s Interventional Cardiology Therapies business. Her renal-denervation and regulatory experience could support innovation and growth in cardiovascular therapies. Recor Medical ex-CEO Lara Barghout joins Medtronic
• Neutral Sentiment: Medtronic’s earnings-call commentary pointed to broad-based growth momentum, while its AI maternal-health initiative with Sonus adds another potential long-term investment theme. Medtronic earnings call signals broad-based growth momentum
• Negative Sentiment: Medtronic underperformed some medical-device peers in the prior session, indicating that investor enthusiasm remains measured despite the improving company-specific news. Medtronic stock underperforms Wednesday compared with competitors

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops, manufactures and sells devices and therapies used to diagnose and treat a broad range of medical conditions. Its products are designed for hospitals, physicians and patients across areas including cardiac care, diabetes, neurological disorders, spinal conditions and surgical procedures.

The company’s portfolio includes pacemakers, implantable cardioverter-defibrillators, cardiac ablation systems, heart valves, neurostimulation systems, implantable pumps, spinal implants and surgical technologies.